Regulatory Roundup: FDA Publishes CDER Presentation, and more. - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Regulatory Roundup: FDA Publishes CDER Presentation, and more.

ePT--the Electronic Newsletter of Pharmaceutical Technology

FDA has published on its website a presentation given by Center for Drug Evaluation and Research (CDER) Director Janet Woodcock on Dec. 9. 2010. The presentation provides a thorough overview of CDER efforts, including the Sentinel initiative, new molecular entity approvals, REMS, and more.

FDA issued on Jan. 7, 2011 another warning about criminals posing as agency officials and other law enforcement personnel as part of a continued international extortion scam. In most cases, criminals call victims who have purchased drugs over the Internet and say they are being charged a fine of $100 to $250,000. Victims are asked to wire the money, and if they do not do so, are often threatened. See the agency’s list of questions and answers about the scam.

The agency has announced a CDER Forum for International Drug Regulatory Authorities to take place April 4–8, 2011, in College Park, MD. The annual forums provide an overview of CDER offices. The 2011 forum will also focus on a product review case study of Etravirine, which is used to treat HIV, to demonstrate how CDER product reviews work. Registration information and requests should be sent to CDERForum@fda.hhs.gov.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here